Ophthalmology HCP Resources

Discover some resources below that you can access to learn more about EYLEA 8 mg in nAMD and DMO.

EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20*, with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.^1–5

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.⁵

Early insights from aflibercept 8 mg: Initiating nAMD and DMO patients in clinical practice

Quick fire cases of EYLEA 8 mg with Dr Kenneth Fan

In this webinar recording, Dr Kenneth Fan discusses 5 patient case studies, sharing his experience of treating both naive and switch patients with nAMD and DMO using EYLEA 8 mg. Dr Fan also answers questions related to EYLEA 8 mg’s safety profile, drying effects and interval extensions drawing upon his experience from the past year.

Prescribing information for EYLEA® (aflibercept) can be found here.

Real-world early user experience with EYLEA 8 mg from a US clinician

In this video, US clinician, Dr Kenneth Fan, discusses real-world outcomes of patients treated with EYLEA 8 mg in the US, including length of treatment intervals reached and initial responses in relation to vision, fluid, and safety profile. Dr Fan also discusses the key challenges and learnings from managing patients with EYLEA 8 mg in a clinical setting. 

Prescribing information for EYLEA® (aflibercept) can be found here.

Clinical papers

The PULSAR and PHOTON 1-Year (48-weeks) primary manuscripts have been published in The Lancet and are now available to download using the links below.^6,7

Formulary resources and support

An updated statement from NICE (The National Institute for Health and Care Excellence) in relation to EYLEA 8 mg in wAMD (wet age-related macular degeneration) link here and DMO (diabetic macular oedema) link here states that “Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294). Therefore, it would not be an efficient use of NHS resources to conduct an evaluation. Aflibercept 8mg should therefore be considered for routine commissioning.”^8,9

As EYLEA 8 mg represents a line extension from the currently available EYLEA 2 mg dose, implementation of EYLEA 8 mg may differ between local health systems. Click on the button below to access some useful resources to support you in your decision making and your formulary update activities across a range of likely scenarios.

Abbreviations

DMO, diabetic macular oedema. HCP, healthcare professional. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service. Q16, every 16 weeks. Q20, every 20 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend. VEGF, vascular endothelial growth factor.

References

1. Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
2. Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
3. Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
4. Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
5. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
6. Lanzetta P, et al. Lancet 2024;403:1141–1152.
7. Brown DM, et al. Lancet 2024;403:1153–1163.
8. NICE (The National Institute for Health and Care Excellence). High-dose aflibercept for treating wet age-related macular degeneration TS ID 10590. Available at: https://www.nice.org.uk/guidance/topic-selection/gid-ta11133. Accessed: August 2024.
9. NICE (The National Institute for Health and Care Excellence). Aflibercept for untreated diabetic macular oedema TS ID 10621. Available at: https://www.nice.org.uk/guidance/topic-selection/gid-ta11134. Accessed: August 2024.